Introduction
Methods
Study patients
Detection of CTCs in peripheral blood
Statistical analysis
Results
Patient characteristics
Stage III IBC
|
Metastatic IBC
| |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Characteristic
|
N
|
%
|
≥1 CTC
a
|
%
|
≥
5 CTC
a
|
%
|
N
|
%
|
≥
1 CTC
a
|
%
|
≥
5 CTC
a
|
%
|
All patients | 77 | 100.0 | 42 | 54.5 | 15 | 19.5 | 70 | 100.0 | 59 | 84.3 | 32 | 45.7 |
Histology | ||||||||||||
Infiltrative ductal carcinoma | 74 | 96.1 | 40 | 54.1 | 15 | 20.3 | 66 | 94.3 | 55 | 83.3 | 31 | 47.0 |
Other histology | 3 | 3.9 | 2 | 66.7 | 0 | 0.00 | 4 | 5.7 | 4 | 100.0 | 1 | 25.0 |
P value | 1.00 | 0.61 | 0.61 | 0.62 | ||||||||
ER/PR status | ||||||||||||
Positive for either | 43 | 55.8 | 19 | 44.2 | 5 | 11.6 | 40 | 57.1 | 33 | 82.5 | 20 | 50.0 |
Negative for both | 34 | 44.2 | 23 | 67.6 | 10 | 29.4 | 30 | 42.9 | 26 | 86.7 | 12 | 40.0 |
P value | 0.06 | 0.08 | 0.74 | 0.47 | ||||||||
HER-2/neu status | ||||||||||||
Overexpressed | 26 | 33.8 | 17 | 65.4 | 7 | 26.9 | 19 | 27.1 | 13 | 68.4 | 9 | 47.4 |
Negative | 51 | 66.2 | 25 | 49.0 | 8 | 15.7 | 51 | 72.9 | 46 | 90.2 | 23 | 45.1 |
P value | 0.23 | 0.36 | 0.04 | 1.00 | ||||||||
Grade | ||||||||||||
High grade | 55 | 71.4 | 32 | 58.2 | 11 | 20.0 | 53 | 75.7 | 43 | 81.1 | 24 | 45.3 |
Intermediate/low grade | 22 | 28.6 | 10 | 45.5 | 4 | 18.2 | 15 | 21.4 | 14 | 93.3 | 8 | 53.3 |
Unknown | - | - | - | - | - | - | 2 | 2.9 | 2 | - | 0 | - |
P value | 0.31 | 1.00 | 0.43 | 0.77 | ||||||||
ER/PR and HER2/neu status | ||||||||||||
Triple receptor negative | 19 | 24.7 | 12 | 63.2 | 5 | 26.3 | 19 | 27.1 | 17 | 89.5 | 7 | 36.8 |
Not-triple receptor negative | 58 | 75.3 | 30 | 51.7 | 10 | 17.2 | 51 | 72.9 | 42 | 82.4 | 25 | 49.0 |
P value | 0.44 | 0.50 | 0.71 | 0.43 | ||||||||
Sites of metastases | ||||||||||||
Non-visceral | - | - | - | - | - | - | 42 | 60.0 | 34 | 81.0 | 18 | 42.9 |
Visceral | - | - | - | - | - | - | 28 | 40.0 | 25 | 89.3 | 14 | 50.0 |
P value | 0.50 | 0.63 | ||||||||||
Bone metastasis | ||||||||||||
Present | - | - | - | - | - | - | 39 | 55.7 | 32 | 82.1 | 19 | 48.7 |
Absent | - | - | - | - | - | - | 31 | 44.3 | 27 | 87.1 | 13 | 41.9 |
P value | 0.70 | 0.63 | ||||||||||
Number of metastases | ||||||||||||
1 | - | - | - | - | - | - | 29 | 41.4 | 22 | 75.9 | 13 | 44.8 |
≥2 | - | - | - | - | - | - | 41 | 58.6 | 37 | 90.2 | 19 | 46.3 |
P value | 0.20 | 1.00 | ||||||||||
Statin use | ||||||||||||
No-statins | 62 | 80.5 | 39 | 62.9 | 14 | 22.6 | 60 | 85.7 | 51 | 85.0 | 30 | 50.0 |
L-statinsb
| 7 | 9.1 | 1 | 14.3 | 1 | 14.3 | 5 | 7.1 | 5 | 100.0 | 1 | 20.0 |
H-statinsb
| 8 | 10.4 | 2 | 25.0 | 0 | 0.0 | 5 | 7.1 | 3 | 60.0 | 1 | 20.0 |
P value | 0.01 | 0.30 | 0.20 | 0.21 | ||||||||
Menopausal status | ||||||||||||
Premenopausal | 27 | 35.1 | 19 | 70.4 | 9 | 33.3 | 25 | 35.7 | 21 | 84.0 | 13 | 52.0 |
Postmenopausal | 50 | 64.9 | 23 | 46.0 | 6 | 12.0 | 45 | 64.3 | 38 | 84.4 | 19 | 42.2 |
P value | 0.06 | 0.03 | 1.00 | 0.46 | ||||||||
Lymphovascular tumor emboli | ||||||||||||
Present | 36 | 46.8 | 20 | 55.6 | 9 | 25.0 | 42 | 60.0 | 37 | 88.1 | 17 | 40.5 |
Absent | 40 | 51.9 | 21 | 52.5 | 6 | 15.0 | 24 | 34.3 | 18 | 75.0 | 12 | 50.0 |
Unknown | 1 | 1.3 | 1 | - | 0 | - | 4 | 5.7 | 4 | - | 3 | - |
P value | 0.64 | 0.39 | 0.19 | 0.61 |
Role of CTCs in IBC
Progression-free survival
|
Overall survival
| |||||||
---|---|---|---|---|---|---|---|---|
Variable
|
Hazard ratio
|
Lower 95% CI
|
Upper 95% CI
|
P
value
|
Hazard ratio
|
Lower 95% CI
|
Upper 95% CI
|
P
value
|
All patients | ||||||||
<1 CTC versus ≥1 CTC | 0.66 | 0.31 | 1.39 | 0.29 | 0.57 | 0.25 | 1.31 | 0.21 |
<5 CTC versus ≥5 CTC | 0.69 | 0.26 | 1.78 | 0.39 | 0.72 | 0.26 | 2.00 | 0.48 |
ER/PR positive for either | ||||||||
<1 CTC versus ≥1 CTC | 0.59 | 0.23 | 1.53 | 0.28 | 0.59 | 0.18 | 1.94 | 0.40 |
<5 CTC versus ≥5 CTC | 0.33 | 0.06 | 1.70 | 0.04 | 0.33 | 0.05 | 2.18 | 0.08 |
ER/PR negative for both | ||||||||
<1 CTC versus ≥1 CTC | 0.76 | 0.22 | 2.69 | 0.69 | 1.14 | 0.55 | 2.39 | 0.70 |
<5 CTC versus ≥5 CTC | 1.14 | 0.31 | 4.14 | 0.85 | 1.05 | 0.28 | 3.91 | 0.94 |
HER-2/neu positive | ||||||||
<1 CTC versus ≥1 CTC | 0.64 | 0.15 | 2.77 | 0.58 | 0.37 | 0.07 | 1.97 | 0.34 |
<5 CTC versus ≥5 CTC | 1.25 | 0.27 | 5.71 | 0.79 | 0.97 | 0.18 | 5.33 | 0.97 |
HER-2/neu negative | ||||||||
<1 CTC versus ≥1 CTC | 0.62 | 0.26 | 1.49 | 0.29 | 0.51 | 0.19 | 1.37 | 0.18 |
<5 CTC versus ≥5 CTC | 0.42 | 0.11 | 1.59 | 0.08 | 0.51 | 0.13 | 2.05 | 0.23 |
Triple negative | ||||||||
<1 CTC versus ≥1 CTC | 0.40 | 0.11 | 1.51 | 0.24 | 0.31 | 0.08 | 1.14 | 0.11 |
<5 CTC versus ≥5 CTC | 0.56 | 0.11 | 2.71 | 0.39 | 0.60 | 0.13 | 2.82 | 0.45 |
High grade | ||||||||
<1 CTC versus ≥1 CTC | 0.65 | 0.28 | 1.47 | 0.31 | 0.42 | 0.17 | 1.06 | 0.09 |
<5 CTC versus ≥5 CTC | 0.56 | 0.19 | 1.69 | 0.22 | 0.44 | 0.13 | 1.46 | 0.09 |
Low/intermediate grade | ||||||||
<1 CTC versus ≥1 CTC | 0.87 | 0.15 | 5.08 | 0.87 | 1.34 | 0.18 | 9.70 | 0.76 |
<5 CTC versus ≥5 CTC | 1.44 | 0.20 | 10.50 | 0.74 | NAa
| NAa
| NAa
| 0.19 |
Progression-free survival
|
Overall survival
| |||||||
---|---|---|---|---|---|---|---|---|
Variable
|
Hazard ratio
|
Lower 95% CI
|
Upper 95% CI
|
P
value
|
Hazard ratio
|
Lower 95% CI
|
Upper 95% CI
|
P
value
|
All patients | ||||||||
<1 CTC vs. ≥ 1 CTC | 0.40 | 0.21 | 0.75 | 0.03 | 0.29 | 0.14 | 0.62 | 0.03 |
<5 CTC vs. ≥ 5 CTC | 0.76 | 0.43 | 1.31 | 0.30 | 0.65 | 0.35 | 1.19 | 0.15 |
ER/PR positive for either | ||||||||
<1 CTC vs. ≥ 1 CTC | 0.30 | 0.13 | 0.67 | 0.03 | 0.14 | 0.05 | 0.37 | 0.02 |
<5 CTC vs. ≥ 5 CTC | 0.57 | 0.27 | 1.20 | 0.13 | 0.54 | 0.24 | 1.22 | 0.14 |
ER/PR negative for both | ||||||||
<1 CTC vs. ≥ 1 CTC | 0.69 | 0.24 | 2.00 | 0.54 | 0.64 | 0.19 | 2.19 | 0.54 |
<5 CTC vs. ≥ 5 CTC | 0.97 | 0.41 | 2.27 | 0.94 | 0.67 | 0.26 | 1.73 | 0.37 |
HER-2/neu positive | ||||||||
<1 CTC vs. ≥ 1 CTC | 0.22 | 0.05 | 0.90 | 0.11 | NA a
| NA a
| NA a
| 0.11 |
<5 CTC vs. ≥ 5 CTC | 0.82 | 0.20 | 3.32 | 0.78 | 0.48 | 0.10 | 2.36 | 0.38 |
HER-2/neu negative | ||||||||
<1 CTC vs. ≥ 1 CTC | 0.75 | 0.32 | 1.72 | 0.53 | 0.52 | 0.21 | 1.29 | 0.26 |
<5 CTC vs. ≥ 5 CTC | 0.66 | 0.36 | 1.22 | 0.16 | 0.58 | 0.30 | 1.14 | 0.09 |
Triple negative | ||||||||
<1 CTC vs. ≥ 1 CTC | 0.92 | 0.22 | 3.79 | 0.91 | 0.79 | 0.20 | 3.04 | 0.74 |
<5 CTC vs. ≥ 5 CTC | 0.34 | 0.10 | 1.14 | 0.01 | 0.35 | 0.10 | 1.28 | 0.02 |
High Grade | ||||||||
<1 CTC vs. ≥ 1 CTC | 0.38 | 0.19 | 0.77 | 0.03 | 0.23 | 0.10 | 0.54 | 0.03 |
<5 CTC vs. ≥ 5 CTC | 0.61 | 0.31 | 1.18 | 0.11 | 0.54 | 0.26 | 1.12 | 0.08 |
Low/intermediate grade | ||||||||
<1 CTC vs. ≥ 1 CTC | 0.75 | 0.12 | 4.54 | 0.77 | 1.05 | 0.13 | 8.45 | 0.96 |
<5 CTC vs. ≥ 5 CTC | 1.30 | 0.44 | 3.87 | 0.61 | 0.87 | 0.28 | 2.71 | 0.81 |
Visceral metastases | ||||||||
<1 CTC vs. ≥ 1 CTC | 0.13 | 0.05 | 0.32 | 0.01 | 0.00 | 0.00 | 0.00 | 0.03 |
<5 CTC vs. ≥ 5 CTC | 0.66 | 0.30 | 1.45 | 0.28 | 0.49 | 0.21 | 1.16 | 0.07 |
Non-visceral metastases | ||||||||
<1 CTC vs. ≥ 1 CTC | 0.66 | 0.28 | 1.56 | 0.39 | 0.62 | 0.22 | 1.77 | 0.44 |
<5 CTC vs. ≥ 5 CTC | 0.87 | 0.40 | 1.88 | 0.71 | 0.78 | 0.33 | 1.83 | 0.55 |
Bone metastasis | ||||||||
<1 CTC vs. ≥ 1 CTC | 0.29 | 0.13 | 0.66 | 0.03 | 0.18 | 0.06 | 0.50 | 0.06 |
<5 CTC vs. ≥ 5 CTC | 0.67 | 0.31 | 1.43 | 0.28 | 0.51 | 0.22 | 1.20 | 0.12 |
No-bone metastasis | ||||||||
<1 CTC vs. ≥ 1 CTC | 0.56 | 0.21 | 1.51 | 0.33 | 0.47 | 0.16 | 1.41 | 0.29 |
<5 CTC vs. ≥ 5 CTC | 0.78 | 0.34 | 1.79 | 0.55 | 0.78 | 0.32 | 1.87 | 0.56 |
Variable
|
PFS
|
OS
| ||
---|---|---|---|---|
HR (95% CI)
|
P
value
|
HR (95% CI)
|
P
value
| |
ER/PR status
| 0.630 | 0.051 | 0.468 | 0.004 |
Positive for either versus negative for both | (0.400 - 1.002) | (0.279 - 0.785) | ||
HER2 status
| 0.309 | <0.001 | 0.268 | <0.001 |
Overexpressed versus negative | (0.173 - 0.554) | (0.138 - 0.521) | ||
Sites of metastases
| 1.536 | 0.143 | 2.319 | 0.002 |
Visceral versus nonvisceral | (0.865 - 2.729) | (1.364 - 3.942) | ||
Stage
| 2.939 | <0.001 | 1.681 | 0.131 |
mIBC versus stage III | (1.818 – 4.750) | (0.857 – 3.298) | ||
Baseline CTCs count
| 1.621 | 0.044 | 1.995 | 0.008 |
≥5 versus <5 | (1.014 - 2.591) | (1.202 - 3.309) |
Relation of Statin and CTCs in IBC
Role of CTCs in Primary IBC
non-pCR (%)
|
pCR (%)
|
P
value
| |
---|---|---|---|
CTC < 1 | 30 (85.7) | 5 (14.3) | 0.39 |
CTC ≥ 1 | 32 (76.2) | 10 (23.8) | |
CTC < 5 | 53 (85.5) | 9 (14.5) | 0.06 |
CTC ≥ 5 | 9 (60.0) | 6 (40.0) |